Overview
After decades of focusing on a few hundred relatively well-characterized therapeutic targets, drug developers are now finding that the genomics revolution has presented them with the opposite dilemma: Many thousands of prospective targets about which little is known, and for which the scant information available is of uncertain accuracy.
Rigorous target validation-the process by which it is determined that a target is causally involved in a disease pathway and that its modulation ameliorates the disease-has traditionally been a painstaking, hypothesis-driven process not well-suited to screening thousands of poorly characterized targets.
Because the ability to quickly identify the most biologically promising of these targets will be the single-largest differentiator between the winners and losers within the research-based pharmaceutical industry over the next decade, tremendous efforts are underway to develop innovative and robust target validation technologies.
This report identifies and critically evaluates the leading target validation technologies and business strategies, with a particular emphasis on recently developed approaches. It also includes detailed, forward looking commentaries by several of the world's leading experts in target validation. | 
View Cart
